Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -130.37% is 50% below its 5-year average of -87.04%, near the low end of its 5-year range (-168.36%–-35.63%).
1.57% below its 12-month average of -128.36%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -30.32%.
RETURN ON ASSETS (ROA)
-130.37%
RETURN ON ASSETS (ROA) AVG TTM
-128.36%
RETURN ON ASSETS (ROA) AVG 3Y
-112.34%
RETURN ON ASSETS (ROA) AVG 5Y
-87.04%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-1.57%
CURRENT VS 3Y AVG
-16.05%
CURRENT VS 5Y AVG
-49.78%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-26.90%
median of 504 covered companies
CURRENT VS SECTOR MEDIAN
-384.65%
vs the sector median at left
Gain Therapeutics, Inc.
Market Cap
$72.09M
Return on Assets (ROA)
-130.37%
TTM Avg
-128.36%
3Y Avg
-112.34%
5Y Avg
-87.04%
Market Cap
$72.02M
Return on Assets (ROA)
-33.34%
TTM Avg
-56.30%
3Y Avg
-89.26%
5Y Avg
-70.59%
Market Cap
$70.03M
Return on Assets (ROA)
-13.50%
TTM Avg
-6.86%
3Y Avg
-33.98%
5Y Avg
-45.40%
Market Cap
$70.01M
Return on Assets (ROA)
-99.89%
TTM Avg
-66.19%
3Y Avg
-52.51%
5Y Avg
-39.81%
Market Cap
$74.35M
Return on Assets (ROA)
-55.32%
TTM Avg
-66.75%
3Y Avg
-58.76%
5Y Avg
-49.95%
Market Cap
$69.43M
Return on Assets (ROA)
35.31%
TTM Avg
-14.11%
3Y Avg
-23.46%
5Y Avg
-20.68%
Market Cap
$68.91M
Return on Assets (ROA)
-3.41%
TTM Avg
5.09%
3Y Avg
-8.30%
5Y Avg
-5.06%
Market Cap
$67.11M
Return on Assets (ROA)
-382.32%
TTM Avg
-98.02%
3Y Avg
-80.35%
5Y Avg
-65.77%
Market Cap
$64.90M
Return on Assets (ROA)
-39.17%
TTM Avg
-30.96%
3Y Avg
-31.81%
5Y Avg
-21.33%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Gain Therapeutics, Inc. (GANX) | $72.09M | -130.37% | -128.36% | -112.34% | -87.04% |
| iBio, Inc. (IBIO)vs › | $72.02M | -33.34% | -56.30% | -89.26% | -70.59% |
| Heron Therapeutics, Inc. (HRTX)vs › | $70.03M | -13.50% | -6.86% | -33.98% | -45.40% |
| MindWalk Holdings Corp. (HYFT)vs › | $70.01M | -99.89% | -66.19% | -52.51% | -39.81% |
| Hyperfine, Inc. (HYPR)vs › | $74.35M | -55.32% | -66.75% | -58.76% | -49.95% |
| Fortress Biotech, Inc. (FBIO)vs › | $69.43M | 35.31% | -14.11% | -23.46% | -20.68% |
| Champions Oncology, Inc. (CSBR)vs › | $68.91M | -3.41% | 5.09% | -8.30% | -5.06% |
| PDS Biotechnology Corporation (PDSB)vs › | $67.11M | -382.32% | -98.02% | -80.35% | -65.77% |
| Alps Group Inc (ALPS)vs › | $64.90M | -39.17% | -30.96% | -31.81% | -21.33% |
| Gossamer Bio, Inc. (GOSS)vs › | $65.08M | -162.91% | -58.42% | -64.67% | -61.98% |
ROA
-130.4%
ROE
-178.1%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -88.35% |
| 2024-12-31 | -168.36% |
| 2023-12-31 | -119.66% |
| 2022-12-31 | -72.99% |
| 2021-12-31 | -35.63% |
| 2020-12-31 | -37.25% |
| 2019-12-31 | -332.20% |
| 2018-12-31 | -136.21% |
